The newly FDA-approved heart failure drug (Entresto®) has caused significant excitement as the clinical studies have shown considerably better therapy outcomes for patients suffering from heart failure.
HyTest was able to continue its strong growth during the first half of 2015. Consolidated revenue grew to 9.2 million euros, which represented an increase of 18% compared to the first half of the previous year.
23.06.2015 HyTest SES-BNP and IGFBP-4 Patents
We are delighted to announce the news that HyTest has been granted a patent in the United States for SES-BNP technology and IGFBP-4 fragments in Finland, France, Germany, Sweden and the United Kingdom.
Our new MAbs and antigens allow detection of CRP in dogs and SAA in dogs, cats and horses.
21.05.2015 Meet HyTest Team at AACC 2015 Atlanta
In July 26-30 HyTest will be participating the 2015 AACC Annual Meeting & Clinical Lab Expo
HyTest has been growing steadily throughout its 20 year history and 2014 was no exception. HyTest’s revenue grew to 16.3 million euros.
Forum of American College of Veterinary Internal Medicine is held in Indianapolis in June 2015. You are welcome to visit our booth #230 on June 4-5.
15.04.2015 First Online Order -15%
Limited time offer: save 15% on your first online order!
29.01.2015 HyTest attends CACLP and IVD Summit in China
HyTest participates the 6th Annual IVD Summit 2015 in Shenzhen, China on March 12-13, 2015 and also the 12th China Association of Clinical Laboratory Practice Expo held in Xiamen, Fujian, 18 – 20, March.
Winner of the grand prize, $20,000 is Professor Paul Collinson from St. George’s, University of London and St. George’s Healthcare NHS Trust. Congratulations!
HyTest participates in Medica exhibition in November 12th - 15th.
03.10.2014 HyTest receives Achiever Certificate 2014
Companies receiving Achiever certification are stable businesses with solid growth, good financial results and profitability.
During the first half of the year, HyTest’s consolidated sales were 7.8 million euros and year-on-year sales grew by 24%. Group operating profit also saw significant growth, reaching 3.4 million euros.
HyTest participates in AACC 2014 Clinical Lab Expo Exhibition in Chicago on July 29-31. You are welcome to visit our booth #3631at any time. Our team is looking forward to see you there!
27.05.2014 HyTest attends ISACP in Copenhagen
HyTest will be present at ISACP 2014 Veterinary Conference. The ISACP will be held on 25-29 of June 2014 in Copenhagen, Denmark.
HyTest turns 20 and reaches a record level of operating profit. While the previous year’s growth figures were not achieved, sales grew steadily throughout the fiscal year.
26.01.2014 HyTest attends IVD Summit and CACLP in China
This March HyTest will be present at this year’s IVD summit and CACLP exhibition. The 11th CACLP exhibition will be held on 5-7 March in Hefei and the 5th IVD Summit will be held in Xiamen on 8-9 March.
Mercodia commercializes HyTest's proprietary IGFBP-4 fragments technology; A novel risk marker for cardiovascular disease
HyTest and Affinity Life Sciences (AFF) have signed a licensing agreement that allows AFF to develop and commercialize a research use only ELISA-kit based on HyTest’s proprietary SES-BNP™ technology.
24.10.2013 HyTest participates in NextDx EU-funded consortium to develop new highly sensitive blood testing technology
eading companies and institutes in protein diagnostics and micro-nano-bio research, including Philips, imec, Hytest, PolyAn, Bremen University and Eindhoven University of Technology, have joined forces